8-K: Prestige Healthcare Acquires Breathe Right for $1.045B

Prestige Consumer Healthcare Inc. announced the acquisition of Breathe Right and other OTC brands for $1.045 billion, expanding its consumer health portfolio.

Summary

• Prestige Brands, Inc., a subsidiary of Prestige Consumer Healthcare Inc., entered into an Asset Purchase Agreement to acquire a portfolio of over-the-counter consumer health products, including Breathe Right and other brands, from Foundation Consumer Brands, LLC.
• The purchase price for the acquisition is $1.045 billion in cash, or approximately $900 million net of anticipated tax benefits valued at $150 million.
• The acquired portfolio generated approximately $200 million in revenue and $95 million in EBITDA over the twelve months ended December 31, 2025.
• Breathe Right, the #1 nasal strip brand, represents approximately two-thirds of the acquired portfolio's revenue and profitability.
• Other acquired brands include Dimetapp, recognized as the #1 most trusted children's cold relief brand by pharmacists, and Anbesol.
• The transaction is expected to close in the first half of Fiscal 2027 (ending September 30, 2026), subject to customary closing conditions and clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
• The acquisition is anticipated to be financed with cash on hand and a new term loan credit facility.
• Pro-forma bank-defined net leverage is expected to be approximately 4.0x at closing, with a clear path to return to the company's long-term target of below 3.0x net leverage in fiscal 2028.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong strategic move, adding a high-margin, category-leading brand that is immediately accretive to key financial metrics and aligns with the company's proven M&A strategy and deleveraging goals.

Positives

• Adds Breathe Right, a leading global brand in the attractive better-breathing category, which is synonymous with its category and holds ~60% market share in nasal strips.
• The acquired portfolio has a highly attractive financial profile with ~70%+ gross margin, ~45%+ EBITDA margin, and strong free cash flow conversion.
• The transaction is immediately accretive to Prestige's revenue, gross margins, EBITDA margins, earnings per share (estimated $0.25+ annualized EPS accretion), and free cash flow.
• Expands Prestige's category footprint and international presence, with ~15% of the acquired revenue being international, primarily in Europe.
• The acquisition aligns well with Prestige's disciplined M&A framework, core competencies, and asset-light business model.
• Expected rapid deleveraging supported by robust free cash flow generation, consistent with prior acquisitions, aiming for a return to long-term leverage target (<3.0x) by fiscal 2028.

Risks

• The ability to meet the closing conditions for the acquisition, including regulatory approvals, could impact the transaction's completion.
• The company's manufacturing operations and third-party manufacturers, logistics providers, and suppliers may face challenges in meeting demand, inflationary cost increases, and supply disruptions.
• Economic, financial market, and business conditions, including interest rates, market volatility, inflation, and geopolitical instability, could adversely affect performance.
• Consumer trends and competitive pressures may impact product demand and market share.
• The effectiveness of advertising, promotional, and new product development initiatives is crucial for sustained growth.
• Customer inventory management initiatives could affect sales volumes.
• The ability to pass along rising costs to customers without negatively impacting sales is a continuous challenge.
• Fluctuating foreign exchange rates and evolving U.S. and international tariffs and trade actions could impact financial results.

Future Outlook

The company expects the acquisition to close in the first half of Fiscal 2027, subject to regulatory approvals. It anticipates rapid deleveraging post-acquisition, aiming to return to its long-term net leverage target of below 3.0x by fiscal 2028, driven by strong free cash flow generation. The acquisition is expected to reinforce Prestige's long-term organic sales growth target of 2-3% and enhance its overall financial profile.

Management Comments

• Ron Lombardi, Chairman, President, and CEO of Prestige Consumer Healthcare, stated, "Today's acquisition fits squarely within our disciplined M&A framework and the Breathe Right brand enhances our portfolio over the long-term."
• Lombardi highlighted, "With its strong consumer awareness, Breathe Right is a trusted, multi-use consumer health solution in the attractive and growing sleep and better-breathing categories, with solid opportunity for long-term brand building."
• He further noted, "Similar to our approach with brands like Dramamine in motion sickness, we're acquiring a brand that is synonymous with its category, providing a strong foundation for sustained growth."
• Lombardi also commented on operational and financial alignment: "Operationally, the business uses a proven, asset-light model whose distribution channels and supplier relationships align well to our current business. Financially, the acquisition is highly attractive with strong margins, and we anticipate it to be accretive to gross and EBITDA margins as well as to EPS. These attributes are expected to drive incremental free cash flow that will enable rapid deleveraging towards the Company's long-term leverage target."

Industry Context

StockSavvy.ai notes that this acquisition positions Prestige Consumer Healthcare to capitalize on the growing demand for over-the-counter consumer health products, particularly in the 'better breathing' and sleep wellness categories. The addition of a category-leading brand like Breathe Right, with its strong brand equity and global reach, strengthens Prestige's competitive standing against other major players in the consumer health sector. The focus on an asset-light model and strong cash flow generation aligns with broader industry trends emphasizing efficiency and shareholder returns in mature consumer goods markets.

Comparison to Industry Standards

• The acquisition of Breathe Right, a #1 brand with ~60% market share in nasal strips, aligns with a strategy of acquiring category leaders, similar to how companies like Johnson & Johnson or Procter & Gamble often integrate dominant brands into their portfolios to leverage existing distribution and marketing strengths.
• The valuation multiple of 11.0x EBITDA (or 9.5x net of tax benefits) for a portfolio with 70%+ gross margins and 45%+ EBITDA margins for established OTC brands is generally considered attractive, especially for brands with strong consumer loyalty and growth potential in stable categories, often commanding higher multiples than average consumer goods acquisitions.
• Prestige's stated goal of rapid deleveraging to below 3.0x net leverage by fiscal 2028, following an initial pro-forma leverage of ~4.0x, demonstrates a commitment to financial discipline that is often benchmarked against peers in the consumer packaged goods and healthcare sectors, where maintaining healthy balance sheets is critical for sustained growth and M&A flexibility.

Stakeholder Impact

• Shareholders: Expected to benefit from immediate accretion to EPS, revenue, and margins, as well as the long-term value creation from a strengthened brand portfolio and rapid deleveraging.
• Customers: Will continue to have access to trusted brands like Breathe Right, Dimetapp, and Anbesol under Prestige's management, potentially benefiting from Prestige's brand-building expertise.
• Employees: The asset-light model and alignment with existing distribution channels suggest a smooth integration, though specific impacts on employment are not detailed.
• Creditors: The company plans to incur new term loan credit facility debt, increasing initial leverage, but commits to rapid deleveraging to its long-term target, which should reassure creditors over time.

Next Steps

• Satisfy or waive customary closing conditions for the acquisition.
• Obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
• Close the transaction in the first half of Fiscal 2027 (ending September 30, 2026).
• File a copy of the Asset Purchase Agreement as an exhibit to the Annual Report on Form 10-K for the year ending March 31, 2026.
• Continue using the Investor Presentation for presentations to investors, analysts, and others during the fourth fiscal quarter ending March 31, 2026, and during the fiscal year ending March 31, 2027.

Key Dates

Recommendation

The acquisition of Breathe Right is a highly strategic move for Prestige Consumer Healthcare, adding a dominant, high-margin brand that is immediately accretive to key financial metrics like EPS, revenue, and EBITDA margins. The company's proven track record of integrating acquisitions and its clear path to rapid deleveraging, despite the initial increase in leverage, demonstrates strong financial discipline. This transaction enhances Prestige's long-term growth algorithm and strengthens its position in attractive consumer health categories, making it a compelling investment opportunity.

Keywords

Prestige Consumer Healthcare, Breathe Right, Acquisition, OTC Consumer Health, Nasal Strips, Dimetapp, Anbesol, Merger, Consumer Brands, Financial Accretion, Deleveraging, EBITDA, SEC Filing